WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
Rosa A van AmerongenRenate S HagedoornDennis F G RemstDanique C AssendelftDirk M van der SteenAnne K WoutersMarian van de MeentMichel G D KesterArnoud H de RuMarieke GriffioenPeter A van VeelenJ H Frederik FalkenburgMirjam H M HeemskerkPublished in: Journal for immunotherapy of cancer (2022)
Our approach resulted in a set of naturally expressed WT1 peptides and four TCRs that are promising candidates for TCR gene transfer strategies in patients with WT1-expressing tumors, including AML and ovarian carcinoma.